85P Adjuvant osimertinib in patients (pts) with stage IB–IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis

Osimertinib is a third-generation, EGFR-TKI with demonstrated efficacy in NSCLC, including CNS metastases. In Chinese pts with NSCLC, prevalence of EGFRm disease is high. In the global phase III ADAURA study (NCT02511106), adjuvant osimertinib demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) vs placebo (PBO) in pts with resectable stage II-IIIA (hazard ratio [HR] 0.17 [99.06% CI: 0.11, 0.26]; p<0.0001) and stage IB-IIIA (HR 0.20 [99.12% CI: 0.14, 0.30]; p<0.0001) EGFRm NSCLC.